| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSTM1 |
| Uniprot No | Q6UX27-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-135aa |
| 氨基酸序列 | MTAEFLSLLC LGLCLGYEDE KKNEKPPKPS LHAWPSSVVE AESNVTLKCQ AHSQNVTFVL RKVNDSGYK QEQSSAENEA EFPFTDLKPK DAGRYFCAYK TTASHEWSES SEHLQLVVTD KHDELEAPS MKTDTRT |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于VSTM1重组蛋白的示例性参考文献(注：以下信息为模拟构造，实际文献需通过数据库检索验证)：
1. **文献名称**: "VSTM1重组蛋白抑制T细胞活化的分子机制研究"
**作者**: Zhang L, et al.
**摘要**: 本研究通过表达纯化VSTM1胞外域重组蛋白，证明其能显著抑制T细胞增殖及IL-2分泌，并通过免疫共沉淀鉴定其与T细胞表面CD28分子的相互作用，提示VSTM1可能作为免疫检查点分子参与自身免疫疾病调控。
2. **文献名称**: "Structural characterization of recombinant VSTM1 and its ligand binding properties"
**作者**: Wang Y, et al.
**摘要**: 利用X射线晶体学解析了VSTM1重组蛋白的胞外结构域三维结构(分辨率2.8Å)，发现其IgV结构域存在独特的电荷分布特征，并通过表面等离子体共振(SPR)证实其与未知受体在pH6.5条件下的高亲和力结合(KD=12nM)。
3. **文献名称**: "VSTM1重组蛋白在类风湿性关节炎中的诊断价值评估"
**作者**: Chen X, et al.
**摘要**: 临床队列研究显示，血清VSTM1重组蛋白检测灵敏度达82%(vs.健康对照组)，其水平与疾病活动度评分(DAS28)呈正相关(r=0.67. p<0.01)，提示其可作为新型生物标志物用于类风湿性关节炎的病情监测。
---
**提示**：实际研究中建议通过PubMed、Web of Science等平台以关键词"VSTM1 recombinant protein"或"VSTM1 immunotherapy"检索，并优先选择近五年内发表于《Nature Immunology》《Journal of Biological Chemistry》等高影响力期刊的文献。
VSTM1 (V-set and transmembrane domain-containing protein 1) is a member of the immunoglobulin (Ig) superfamily, characterized by its extracellular V-set Ig-like domain and a transmembrane region. Initially identified as a cell surface protein expressed primarily in immune cells, including T cells, B cells, and monocytes, VSTM1 has garnered attention for its potential role in immune regulation. Its gene, located on human chromosome 7p12.3. encodes a type I transmembrane protein with conserved structural features across species, suggesting evolutionary significance in immune signaling pathways.
Functionally, VSTM1 is proposed to act as a co-inhibitory receptor, modulating immune cell activation. Studies indicate it may suppress T-cell proliferation and cytokine production upon interaction with ligands (still under characterization), potentially serving as a checkpoint molecule akin to PD-1 or CTLA-4. This immunomodulatory activity positions VSTM1 as a candidate target for cancer immunotherapy or autoimmune disease treatment. However, its precise mechanisms and signaling partners remain incompletely understood, necessitating further research.
Recombinant VSTM1 protein, produced via heterologous expression systems (e.g., HEK293 or *E. coli*), enables structural and functional studies. Purified soluble forms (e.g., extracellular domains) facilitate ligand-binding assays, receptor interaction mapping, and antibody development. Recent work explores its therapeutic potential: blocking VSTM1 in preclinical models enhances anti-tumor immunity, while agonistic approaches might curb excessive inflammation. Challenges include optimizing protein stability for *in vivo* applications and resolving conflicting data regarding its pro- versus anti-inflammatory effects across different cellular contexts. Current research focuses on elucidating its physiological ligands, downstream signaling, and disease-specific roles to guide clinical translation.
×
